Targeting both stem-like and regular prostate cancer cells
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells
New treatments that hit both stem-like and regular prostate cancer cells for men with advanced, treatment-resistant prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11306663 on NIH RePORTER |
What this research studies
Researchers are developing therapies that attack both the common prostate cancer cells and a harder-to-kill stem-like cell type that can drive treatment resistance. The team uses patient tumor samples, cell models, and animal studies to discover drug targets and test drug combinations that can eliminate both cell populations. They focus especially on cancers with low or no androgen receptor (AR), which often expand after anti-androgen therapy. The aim is to prevent or slow progression to metastatic castration-resistant prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates are men with advanced or metastatic prostate cancer, particularly those who have progressed after androgen-deprivation or anti-androgen therapies.
Not a fit: Men with early-stage, localized prostate cancer or people without prostate cancer are unlikely to receive direct benefit from this research at present.
Why it matters
Potential benefit: If successful, these approaches could reduce recurrence and slow progression of advanced, treatment-resistant prostate cancer.
How similar studies have performed: Some preclinical and clinical combination approaches with anti-androgens have shown promise, but specifically targeting AR-low stem-like prostate cells is a newer and less tested strategy.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Tang, Dean G. — Roswell Park Cancer Institute Corp
- Study coordinator: Tang, Dean G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.